In marketing, multi-faceted marketing planning and a complete set of marketing strategies are very important, so as to ensure stability and orderly progress. This requires pharmaceutical companies to streamline various relationships in the marketing planning process, such as the formulation of product prices, the selection of regional markets, etc., should have a precedence and priorities. The planning of "same treatment" will cause problems if it is truly implemented.
After the first product research, many pharmaceutical companies often engage in market research and then determine the product, in the hope that this will increase the insurance factor of the product after listing. In fact, market research without target products is very blind, and it is often just a kind of empirical behavior of pharmaceutical companies. They do not have the patience to conduct an intensive investigation of the audience market. When the products pass a clinical trial, they are listed on the market. It is basically over. In the case of some large pharmaceutical companies, the marketing departments of drug companies are also often useless. Their responsibility is to promote products rather than market research, because, to a large extent, planning is the leader's task and the marketing department cannot be the master. Therefore, when pharmaceutical companies let market departments investigate a certain category of market, most of them copy some data from the Internet, and then get some information from the sales staff, and the investigation is over. What kind of products and products the company should develop should be aimed at specific groups of people. Therefore, regardless of whether the pharmaceutical company is doing overall planning or product planning, it should be based on the principle of research after the first product and be targeted. If pharmaceutical companies always make brainstorming programs, the execution of some departments will be greatly reduced.
The lack of marketing direction after the first direction planning is an important reason for the failure of product marketing planning. Some pharmaceutical companies believe that the product's indication is the market direction of the product, such as the treatment of rheumatic drugs. The idea of ​​drug company planning is to determine the regional market and come up with appropriate marketing programs to promote the product. In fact, pharmaceutical companies still have not determined the direction of good products, such as product channel issues, terminal coverage issues, and after-sales service issues. When a family drug company transfers a health product from the high-end market to the low-end market, it simply determines the marketing channel. As for prices, promotion, etc., it still continues the strategy in the high-end market, resulting in the direction of the product is not clear. Marketers also believe that marketing managers do not have a good planning idea for the product and lose confidence in the product. From this point of view, when a pharmaceutical company is doing marketing planning, it should first determine the direction of the product, and then plan the product before it is conducive to the long-term development of the product.
After the analysis, the marketing department planning the pharmaceutical company shall analyze the utilization value of the data comprehensively no matter how it collects the data. For example, which data are too questionable, which markets are more suitable for the development of the product, and which methods are not suitable for the development? Product promotion and so on. Some drug companies rely too much on the data they have collected to develop marketing strategies based on data. However, the "absoluteness" of the data will affect the "relativeness" of the marketing strategy. One of the reasons for the failure of some pharmaceutical companies to plan a product is to blindly and optimistically rely on the data to make plans, make plans, and set targets, leading to dislocation from the market. , thereby affecting the normal play of a planning program. Marketing planning before drug listing is very important. It affects the healthy development of a product in the market and the size of the development space. Pharmaceutical companies must make more efforts to analyze it, and must establish the plan based on an accurate, credible and authoritative investigation. On top of the analysis, blind marketing should not be targeted.
After the first product research, many pharmaceutical companies often engage in market research and then determine the product, in the hope that this will increase the insurance factor of the product after listing. In fact, market research without target products is very blind, and it is often just a kind of empirical behavior of pharmaceutical companies. They do not have the patience to conduct an intensive investigation of the audience market. When the products pass a clinical trial, they are listed on the market. It is basically over. In the case of some large pharmaceutical companies, the marketing departments of drug companies are also often useless. Their responsibility is to promote products rather than market research, because, to a large extent, planning is the leader's task and the marketing department cannot be the master. Therefore, when pharmaceutical companies let market departments investigate a certain category of market, most of them copy some data from the Internet, and then get some information from the sales staff, and the investigation is over. What kind of products and products the company should develop should be aimed at specific groups of people. Therefore, regardless of whether the pharmaceutical company is doing overall planning or product planning, it should be based on the principle of research after the first product and be targeted. If pharmaceutical companies always make brainstorming programs, the execution of some departments will be greatly reduced.
The lack of marketing direction after the first direction planning is an important reason for the failure of product marketing planning. Some pharmaceutical companies believe that the product's indication is the market direction of the product, such as the treatment of rheumatic drugs. The idea of ​​drug company planning is to determine the regional market and come up with appropriate marketing programs to promote the product. In fact, pharmaceutical companies still have not determined the direction of good products, such as product channel issues, terminal coverage issues, and after-sales service issues. When a family drug company transfers a health product from the high-end market to the low-end market, it simply determines the marketing channel. As for prices, promotion, etc., it still continues the strategy in the high-end market, resulting in the direction of the product is not clear. Marketers also believe that marketing managers do not have a good planning idea for the product and lose confidence in the product. From this point of view, when a pharmaceutical company is doing marketing planning, it should first determine the direction of the product, and then plan the product before it is conducive to the long-term development of the product.
After the analysis, the marketing department planning the pharmaceutical company shall analyze the utilization value of the data comprehensively no matter how it collects the data. For example, which data are too questionable, which markets are more suitable for the development of the product, and which methods are not suitable for the development? Product promotion and so on. Some drug companies rely too much on the data they have collected to develop marketing strategies based on data. However, the "absoluteness" of the data will affect the "relativeness" of the marketing strategy. One of the reasons for the failure of some pharmaceutical companies to plan a product is to blindly and optimistically rely on the data to make plans, make plans, and set targets, leading to dislocation from the market. , thereby affecting the normal play of a planning program. Marketing planning before drug listing is very important. It affects the healthy development of a product in the market and the size of the development space. Pharmaceutical companies must make more efforts to analyze it, and must establish the plan based on an accurate, credible and authoritative investigation. On top of the analysis, blind marketing should not be targeted.
Food Condiments,Low Sodium Condiments,Table Condiments,Healthy Condiments
COFCO HEBEI INTERNATIONAL TRADING CO., LTD. , https://www.cofcohb.com